Decision: Favourable

Decisions Table

Study Title:

A Phase 3, Randomized, International Multicenter Trial Of DAY101 Monotherapy Versus Standard Of Care Chemotherapy In Patients With Pediatric Low-Grade Glioma Harboring An Activating RAF Alteration Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  • NREC Code:

    22-NREC-CT-167

  • Decision:

    Favourable

  • Meeting Date:

    09/11/2022

  • Study Type:

    CT Application

  • Principal Investigator:

    Dr Sarah Curry

  • PI Institution:

    CHI Crumlin

  • Sponsor:

    Day One Biopharmaceuticals, Inc. (Day One)

Scroll to Top